Targretin bexarotene capsules: Phase II data; Marketed to treat refractory cutaneous T cell lymphoma (CTCL)

LGND presented interim data from 3 of 4 dosage groups in its 37-patient European Phase II trial

Read the full 175 word article

How to gain access

Continue reading with a
two-week free trial.